- Home
- MIRM vs EAT Comparison
MIRM vs EAT Comparison
Compare MIRM & EAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | EAT |
|---|---|---|
| Founded | 2018 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.1B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MIRM | EAT |
|---|---|---|
| Price | $84.87 | $193.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 23 |
| Target Price | $153.43 | ★ $256.73 |
| AVG Volume (30 Days) | 696.6K | ★ 1.1M |
| Earning Date | 11-10-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | 30.65 |
| EPS | N/A | ★ 10.87 |
| Revenue | $19,138,000.00 | ★ $5,807,400,000.00 |
| Revenue This Year | $33.91 | $8.34 |
| Revenue Next Year | $17.40 | $2.93 |
| P/E Ratio | ★ N/A | $17.33 |
| Revenue Growth | N/A | ★ 7.86 |
| 52 Week Low | $63.23 | $100.30 |
| 52 Week High | $130.00 | $254.99 |
Technical Indicators
Market Signals| Indicator | MIRM | EAT |
|---|---|---|
| Relative Strength Index (RSI) | 48.71 | 47.31 |
| Support Level | $78.07 | $192.50 |
| Resistance Level | $88.31 | $212.23 |
| Average True Range (ATR) | 3.72 | 8.64 |
| MACD | 0.80 | 0.04 |
| Stochastic Oscillator | 66.21 | 42.30 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About EAT Brinker International Inc.
Brinker International is a leading casual dining operator and franchisor. Chili's, its largest banner and the second-largest casual dining concept in the US, is known for its American/Southwest-inspired menu. In fiscal 2026, the segment generated $5.3 billion in revenue (92% of consolidated sales) across 1,114 company-owned restaurants in the US and 469 franchised locations (the bulk of which are in international markets). The Italian casual-dining concept Maggiano's accounts for the remainder of the business, with 52 domestic units.